3rd Annual RAS Targeted Drug Development Summit 11:30 a.m. ET
Sep 22, 2021
Phase 1/2 Trial of Rigosertib & Nivolumab in KRAS-Mutated NSCLC in 2nd+ Line presented by Rajwanth Veluswamy, MD MSCR, Assistant Professor of Medicine, Icahn School of Medicine at Mount Sinai, NYC